reports
Preferred Bank (Los Angeles, CA): 2 directors
A director at Preferred Bank (Los Angeles, CA) sold 900 shares at 78.080USD and the significance rating of the trade was 38/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
CoreCard Corporation Reports First Quarter 2024 Results
CoreCard Corporation Reports First Quarter 2024 Results NORCROSS, Ga., May 02, 2024 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended March 31, 2024. "Overall revenue of $13.1 million in the first quarter was in-line with our expectations, reflecting continued year-over-year growth in processing and maintenance of 13%, which was offset by lower professional ser...
- FIMA Research
Fima Daily Insight 02 May 2024
Please find enclosed our daily market report.Market CommentCroatia AD Plastik boosts net profit in Q1 Podravka Q1 net profit surges 48% YoY Hrvatski Telekom’s Q1 net profit down 1.7% SPAN plans to pay EUR 0.30 share dividend (DIVY 0.7%) Croatia's retail sales volume up real 8.9% in March Slovenia Slovenia's annual inflation rate down 0.6 p.p. in April to 3% Romania Transport Trade Services shareholders approve distribution of RON 68.4 mil as dividends Bulgaria Speedy nea...
Context Therapeutics Announces FDA Clearance of IND Application for a ...
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6...
Parker Reports Fiscal 2024 Third Quarter Results
Parker Reports Fiscal 2024 Third Quarter Results Sales were a record at $5.07 billion; organic sales increased 1%Segment operating margin was 21.5%, or a record 24.7% adjusted, an increase of 150 basis pointsEPS were $5.56, or a record $6.51 adjusted, an increase of 10%Company increases outlook for segment operating margin and EPS2024 Investor Meeting scheduled for May 16 at 2 p.m. Eastern time CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the fiscal 2024 third quarter e...
Map Aktif Adiperkasa Tbk PT: 1 director
A director at Map Aktif Adiperkasa Tbk PT bought 3,700,000 shares at 800.000IDR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Capricorn Metals Ltd: 1 director
A director at Capricorn Metals Ltd sold 2,011,539 shares at 4.900AUD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the c...
Biogen Reports Progress on Corporate Responsibility Priorities
Biogen Reports Progress on Corporate Responsibility Priorities Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) today announced publication of its detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders. “As we reflect on the past year and set our sights on the path ahead, I am truly inspired by the progress we have made to advance Biogen’s enduring legacy of pioneering inno...
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacoki...
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today ann...
Oma Säästöpankki Oyj: Johdon liiketoimet – Jarmo Salmi
Oma Säästöpankki Oyj: Johdon liiketoimet – Jarmo Salmi OMA SÄÄSTÖPANKKI OYJ, PÖRSSITIEDOTE 2.5.2024 KLO 14.30, JOHTOHENKILÖIDEN LIIKETOIMET Oma Säästöpankki Oyj: Johdon liiketoimet – Jarmo Salmi Ilmoitusvelvollinen: Nimi: Jarmo Salmi Asema: Hallituksen jäsen/varajäsen Liikkeeseenlaskija: Oma Säästöpankki OyjLEI: 743700LE1ECAPXC5UT18Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 60910/5/4Liiketoimen päivämäärä: 2.5.2024Kauppapaikka: NASDAQ HELSINKI LTD (XHEL)Liiketoimen luonne: HANKINTAInstrumenttityyppi: OSAKEISIN: FI4000306733 Liiketoimien yksityiskohtaiset tiedot(1): Volyymi:...
Altimmune to Report First Quarter 2024 Financial Results and Provide B...
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at . Participants who woul...
AppTech Payments Corp. to Present at Sidoti Virtual Investor Conferenc...
AppTech Payments Corp. to Present at Sidoti Virtual Investor Conference May 8-9 CARLSBAD, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce, announced Luke D’Angelo, Chairman & CEO, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 8-9, 2024. The presentation will begin at 4 PM ET on May 8, 2024 and can be accessed live here: . AppTech will also host virtual one-on-ones with investors on Wednesday and Thursday, May 8-9, 2024...
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial ...
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ET NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corp...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court date scheduled for April 21, 2025 Strong financial position – expected cash runway extended throu...
GURU Organic Energy Enters Zero Sugar Segment With Metabolism-Boosting...
GURU Organic Energy Enters Zero Sugar Segment With Metabolism-Boosting GURU Zero Wild Berry ZERO SUGAR: fastest growing energy drink segment in Quebec1 and the US2 as more consumers seek low-calorie, sugar-free energy drinks.METABOLISM BOOST: EGCG and catechins, a form of green tea polyphenols, are clinically studied for their potent antioxidant effects and metabolism boosting when combined with caffeine. This metabolism boost helps burn more calories and convert energy faster to support active lifestyles and improved physical performance.Initial launch in retail stores in Quebec and online...
GURU Organic Energy fait son entrée dans le segment sans sucre avec GU...
GURU Organic Energy fait son entrée dans le segment sans sucre avec GURU Zéro Baies sauvages qui boost le métabolisme ZÉRO SUCRE : le segment des boissons énergisantes qui connaît la plus forte croissance au Québec1 et aux États-Unis2, alors que plus de consommateurs recherchent des boissons énergisantes à faible teneur en calories et sans sucre.BOOST LE MÉTABOLISME : l'EGCG et les catéchines, une forme de polyphénols du thé vert, ont fait l'objet d'études cliniques pour leurs puissants effets antioxydants et leur capacité à accélérer les fonctions métaboliques lorsqu'ils sont associés à la...
MGP Ingredients Reports First Quarter 2024 Results
MGP Ingredients Reports First Quarter 2024 Results Q1 results in line with expectations; Reiterates annual guidance ATCHISON, Kan., May 02, 2024 (GLOBE NEWSWIRE) -- MGP Ingredients, Inc. (Nasdaq: MGPI), a leading provider of branded and distilled spirits as well as food ingredient solutions, today reported results for the first quarter ended March 31, 2024. 2024 first quarter consolidated results compared to 2023 first quarter: Due to the Atchison distillery closure, sales decreased 15% to $170.6 million. Excluding the impact of the Atchison distillery in both periods, consolidated sa...
Volt Lithium Announces Closing of US$1.5 Million Strategic Investment
Volt Lithium Announces Closing of US$1.5 Million Strategic Investment Not for distribution to United States newswire services or for dissemination in the United States. CALGARY, Alberta, May 02, 2024 (GLOBE NEWSWIRE) -- Volt Lithium Corp. (TSXV: VLT | OTCQB: VLTLF) (“Volt” or the “Company”) is pleased to announce that it has closed its previously announced non-brokered private placement of 6,818,182 units of Volt (“Units”) issued to a strategic investor (the “Investor”) at a price of US$0.22 per Unit for aggregate consideration of US$1,500,000 (the “Strategic Investment”) effective May...
Context Therapeutics Announces $100 Million Private Placement
Context Therapeutics Announces $100 Million Private Placement Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.